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Summary
Anti-FcyR IgM monoclonal antibodies (mAbs) isolated from lipopolysaccharide-stimulated
spleen cellsfrom tightskin (TSK) mice were found to be polyspecific, reacting with a wide variety
of molecules, including double-stranded DNA, topoisomerase, RNA polymerase, and different
collagen types. Approximately 60% of the polyspecific IgM mAbs have anti-Fr,R specificity.
These anti-FoyR mAbs induce the release of hydrolases from both azurophil and specific granules
ofhuman neutrophils. 25-45% of the total cellular content (determined in Nonidet P-40 lysates)
of neutrophil elastase, 10-25% of fl-glucuronidase, and 30-50% of alkaline phosphatase was
released afterincubation with the mAbs. The degranulation process was accompanied by dramatic
morphological changes shown by scanning and transmission electron microscopy. The release
of hydrolytic enzymes stimulated by the IgM . anti-FcyR mAbs was inhibited by preincubation
of neutrophils with Fab fragments of either anti-human FcYRII (IV3) or anti-human FcyRIII
(3G8) mAbs. The binding of the anti-FcyR TSK mAbs to human neutrophils was inhibited
by Fab fragments of mAb 3G8. However, we found that the TSK anti-Fc,R mAbs do not bind
to human Fc,RII expressed in either CHO cells or the P388D1 mouse macrophage cell line.
Since the enzyme release could be inhibited by Fab fragments of mAb IV3, we suggest that
the signal transduction may require FcyRII activation subsequent to crosslinking of the glycan
phosphatidyl inositol-anchored FcyRIII-1. These data demonstrate for the first time that
polyspecific autoantibodies with FcyR specificity can trigger neutrophil enzyme release via
human FcyRIII-1 in vitro and indicate a possible role for such autoantibodies in autoimmune
inflammatory processes.
Organ injury due to inflammatory processes is a fun-
damental sign ofmany autoimmune diseases. Autoan-
tibodies and immune complexes that are the hallmark of au-
toimmunity can trigger inflammation by several pathways.
Immune complexes can activate the complement system
resulting in generation of chemotactic peptides and deposi-
tion of C3b and C3bi, which are ligands for complement
receptors on neutrophils and macrophages. Immune complexes
may also interact directly with FvyP s on effector cells, re-
sulting in release ofhydrolases, activated oxygen intermediates,
and cytokines (1, 2). Other autoantibodies upon interaction
with their antigens such as acetylcholine receptor directly
trigger pathogenic events (3).
We have recently reported the presence of high levels of
anti-FcyR autoantibodies in different mouse strains prone to
autoimmune diseases such as NZB, NZB/NZW Tightskin
(TSK)', and viable-motheaten (4). Moreover, some IgM
'Abbreviations used in this paper: DHFR, dihydrofolate reductase; GPI,
glyran phosphatidyl inositol; PSS, progressive systemic sclerosis; TSK,
tightskin.
mAbs generated from spleen cells of these animals bound to
murine FcyRII. The mAbs with FcyR specificity comprise
a subset (60%) of polyspecific IgM mAbs. Both serum from
autoimmune mice and IgM anti-FcyR mAbs were able to
inhibit specifically the binding of immune complexes in vitro
to macrophages. These anti-FcyR autoantibodies may be
responsible for the paralysis of macrophage FcyR function
seen in peritoneal macrophages isolated from autoimmune
mice (5).
Human anti-FcyR receptor antibodies have been demon-
strated in SLE andjuvenile neutropenia (6-8). Furthermore,
in diseases such as Sjogren's syndrome, rheumatoid arthritis,
and lupus (9), there is often a paralysis of FcyR function
similar to that observed in the murine models for autoim-
munity. Functional studies are required to assess the impor-
tance of these polyspecific anti-Fr-,R antibodies in the pa-
thology of autoimmune disease. In this report, we present
evidence that anti-FcyR autoantibodies have a profound
effect on human neutrophils, resulting in release of hydro-
lytic enzymes contained in both specific and azurophil granules.
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Monoclonal Antibodiesfrom TSKMice.
￿
Splenic lymphocytes from
2- and 10-mo-old TSKmice, stimulated with LPS (25 Ag/ml) for
2 d, were fused with SP2/0 myeloma cells as described (10, 11).
Supernatants from hybridomas were tested by an ELISA for binding
to truncated mouse Fc,,RII0 (12) that was coated onto microtiter
wells (4) . The truncated Fc,.RI10 contained only the extracellular
domains of the receptor. To prevent nonspecific binding via the
Fc domain, the truncated Fc,.R was denatured by reduction and
alkylation . 5 of440 hybridomas had specificity for Fc,.R, and these
hybridomas were expanded andcloned by limiting dilution . Anti-
bodies were purifiedby affinity chromatography on a rat anti-mouse
rc-specific mAb Sepharose-4B column . All the anti-Fc,R mAbs
were of the IgM class .
Isolation ofHuman Neutrophils.
￿
Peripheral blood drawn from
healthy individuals was anticoagulated with heparin and diluted
1:3 with HBSS. The blood (20 ml) was carefully layered on top
ofa two-step gradient made from 1.119 g/ml Ficoll and 1.077 g/ml
Ficoll (10ml each) (Sigma Chemical Co ., St . Louis,MO) (13) . After
centrifugation (23min, 24°C, 1,000 g) in a swinging bucket rotor,
the neutrophils were collected, washed, andresuspended inRPMI
containing 10% FCS.
Expression ofHuman Fc.,RII in P388DI andCHO Cells.
￿
We
obtained a human (hu) Fc,.RIIa cDNA (14, 15) that was cloned
into the EcoRI restriction site of the pGEM-4 vector from Dr .
Kochan (Hoffman LaRoche, Nutley, NJ) . The cDNA was then
subcloned into the EcoRl site ofpcEXV3 (16), a eukaryotic ex-
pression vector with an SV40 early gene promoter. PlasmidDNA
from both positive (expressing) orientation and negative orienta-
tion huFc,.Rlla-containing bacterial transformants was purified on
aCsCl gradient (17) for use in calciumphosphate-DNA coprecipi-
tate transfections as described (18) . Dihydrofolate reductase(DHFR)-
negative CHO cells (DG44) were cotransfected with huFcRI1a-
pcEXV3 and aDHFR minigene-containing plasmid, pMG1(19) .
CHO transfectants were selected using hypoxanthine-deficient
media . P388D1 cells were cotransfected with huFcRIla-pcEXV3
andLK444 (20), aplasmid with a neomycin resistance gene. The
only modification ofthe calciumphosphate coprecipitation method
required to transfect the P388D1 cellswas the addition of 10014M
chloroquine (Sigma Chemical Co.) to the transfection media .
P388D1 transfectants were selected by adding 200 mg/liter of
Geneticin (Sigma ChemicalCo.) to thegrowth media . The ability
oftransfectants to bind mAbIV3, an anti-huFcRII antibody, was
analyzed on an Epics cytofluorograph (Coulter Electronics Inc.,
Hialeah, FL) with three decades of amplification (21) .
Binding Studies.
￿
mAbs 3G8, TSKI, TSK22, TSK26, andTSK40
were conjugated with FIX (22) . 5 x 105 neutrophils were in-
cubated in 0.25 ml with the antibodies (1 Etg/ml) for 45 min on
ice . The cells were then washed and fixed with 3% paraformalde-
hyde in PBS. Analysis was done on an Epics cytofluorograph with
three decades of amplification. Mean fluorescence peak channels
were converted to relative fluorescence to facilitate comparison of
inhibition and binding studies. To quantify the amount of FITC-
Ig bound per cell, the fluorescence of appropriate dilutions of the
FITC-conjugated Ig and stained cellswas determined in a fluores-
cence spectrometer (650-10S; The Perkin-Elmer Corp., Norwalk,
CT) with excitation andemission monochromators set at 480and
520 nm, respectively.
Stimulation ofNeutrophils by Anti-fc.,.R Autoantibodies .
￿
Neutro-
phils suspended inRPMI supplemented with 10% FCSwere plated
in 24-well tissue culture plates (Costar Electronics Inc.) at 10 6
cells/well . The original medium was removed after 30 min and
1474
replaced with 1 ml of Ig (0.01-10 mg/ml) diluted in RPMI con-
taining 10% FCS . Aliquots of cell supernatants were taken at in-
tervals to follow the course of enzyme release. In blocking experi-
ments to study the effect of the anti-Fc,,RIII mAb 3G8 and the
anti-Fc,RII mAb IV3, the mAbs (or their Fab fragments) were
added to the cells for 1 h before they were replaced with the anti-
Fc,R autoantibodies. mAb IV3 and its Fab fragment were pur-
chased from Medarex(Hanover, NH) . mAb3G8and3G8-Fab were
prepared in our laboratory as described (23) .
Enzyme Assays.
￿
All enzyme determinations were carried out
on 96-well microtiter plates in triplicate . To quantify enzyme re-
lease, dilutions of neutrophil-conditioned supernatants or lysates
were mixed with appropriate substrates and buffers and read in a
microplate reader (MR600; Dynatech Laboratories Inc., Alexan-
dria, VA) . /3-glucuronidase was assayed by cleavage of phenol-
phthalein-/3-glucosiduronic acid (Sigma Chemical Co .) as described
(24) . Supernatant (501Al) was added to the substrate (30 Al of 3 .3
mM phenolphthalein-/3-glucosiduronic acid in 0.067 M acetate
buffer,pH 4.5) . After incubation (3 h, room temperature) the reac-
tion was developed by addition of glycine buffer (20 pl, 0.4 M,
pH 10.5) and read at 540nm . Neutrophil elastase activity was as-
sayed by the cleavage of N-t-BOC-ala-pro-nva thiobenzyl ester
(Sigma Chemical Co.) in the presence of 5,5'-dithio-bis-(2-nitro-
benzoic acid) (Ellman's reagent) (PierceChemical Co ., Rockford,
IL), which reacts with the free sulfhydryl of the liberated thio-
benzyl group (25) . Supernatant (25 Al) was added to the reaction
mixture (75 ul, 4.5 mM peptide, 0.33mM Ellman's reagent, in
PBS, pH 7.4, containing 10% DMSO), incubated at room tem-
perature for 1 h, and read at 410nm . Alkaline phosphatase activity
was measured by cleavage ofp-nitrophenyl phosphate (26) . Super-
natant (50 Al) was added to the reaction mixture (50 Al, 6 mM
p-nitrophenyl phosphate, 1mM ZnCI2, 1MM MgC12, 0.1 M gly-
cine buffer, pH 10.0), incubated at 37°C for 1 h, and read at 410
nm . To determine total cellular enzyme content, neutrophils were
lysed with 1 ml of0.5%NP40 for 10 min, and cleared of nuclei
and particulate matter by centrifugation (20min at 14,000 g) . The
cleared lysate supernatant was used in assays for determinations of
total cellular enzyme .
Scanning Electron Microscopy.
￿
Neutrophils (106 cells/well) were
plated on round coverslips (12mm diameter, no. 1) (PropperSGA
Scientific Inc., Bloomfield, NY) in 24-well tissue culture plates in
RPMI containing 10% FCS . After30 min, complete medium con-
taining the different anti-Fc,.R antibodies was added. At intervals,
the antibody-containing medium was removed and the cells were
fixed for 30 min (1.5% glutaraldehyde in 0.1 Mcacodylate buffer,
pH 7.4) and postfixed (1% osmium in 0.1 M cacodylate buffer)
(27) for 1 h. The coverslips were dehydrated, critical point dried,
and viewed in a scanning electron microscope (S-530 ; Hitachi) at
6,000x . Some duplicate coverslips were kept in 1% cacodylate buffer
after osmium treatment . These coverslips were examined using a
50 x objectivewith Nomarsky (differential interference optics)on
an Axiomat microscope (Carl Zeiss, Inc., Thornwood, NJ) .
Transmission Electron Microscopy.
￿
For transmission electron mi-
croscopy, neutrophils were incubated with the anti-Fc,,R mAbs or
controls in suspension . After fixation (2% glutaraldehyde in 0.1M
cacodylate buffer, 1 MM C2C12) for 30 min, the cells were col-
lected by centrifugation and postfixed(1%reducedosmium in0.1 M
cacodylate buffer) (27) for 1 hon ice.Thesampleswere dehydrated,
embedded,and silver-gold sections cuton amicrotome(MT5000;
Sorvall) . The grids were stained with uranyl acetate and lead ci-
trate (28, 29) andphotographed at x8,000 on an electron micro-
scope (H-7000; Hitachi) .
IgM Anti-FcyR Autoantibodies Trigger Neutrophil DegranulationResults
TSK mice are considered to be a good animal model of
human progressive systemic sclerosis (PSS) . These mice de-
velop a scleroderma-like syndrome, accompanied with cuta-
neous hyperplasia and increased transcription ofcollagen genes
(30, 31) . The oldTSK mice also produce autoantibodies for
topoisomerase I (11), which are characteristic for human
progressive systemic sclerosis and are not found in patients
with morphea or CREST syndrome (32). Because the highest
levels of circulating anti-FcyR autoantibodies were found in
sera ofTSK mice (4), we isolated monoclonal anti-FcyR au-
toantibodies from TSK mice and investigated the possible
functional effect of those antibodies.
Characterization of Anti-FcyR IgM Antibodies from TSK
Mice . 440 LPS-stimulated hybridomas generated from old
TSK mice were screened with different antigens known to
be targets of scleroderma autoantibodies . All the screening
for anti-FcyR mAbs was done on microtiter plates coated
with reduced and alkylated truncated Fc yRII0 (12) . The
mAbs obtained therefore do not depend upon native confor-
mation of the FcyR for binding, as do the two anti-Fc yR
mAbs 3G8 (anti-human FcyRIII) and 2AG2 (anti-rnurine
FcyRII) . The mAbs that were identified in the ELISA for
anti-FcyR mAbs were examined further for binding to
topoisomerase I, RNA polymerase, collagen I and III, and
dsDNA. TheTSK antibodiesweidentified in the initial screen
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Figure 1.
￿
Staining of human neutrophils with IgM anti-FcyR mAbs.
Human neutrophils (5 x 105 cells/sample) were incubated with directly
FITC-labeled mAbs 3G8, TSKI, TSK22, TSK23, TSK26, and TSK40 (1
Wg/ml) for 45 min on ice. The mean fluorescenceintensities of thedifferent
samples were: unstained, 2.428 ; isotype control (mouse IgM), 8.867; 3G8,
208.4; TSK1, 159.1 ; TSK22, 85.54; TSK23, 85.54; TSK26, 76.79 ; TSK40,
142.8.
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Neutrophils (106 cells/sample) were incubated with FITC-conjugated an-
tibodies, as described, on ice for 45 min . For the inhibition experiment,
cells were preincubated with indicated concentrations of3G8 Fab for 1 h,
washed twice by centrifugation, and stained with FITC-TSKI . Arbitrary
fluorescence units from the fluorescence spectrometer are shown .
were all polyspecific, and constitute a subset (60%) ofall poly-
specific antibodies found, whichwe defined as mAbs reacting
with three disparate antigens. Within the subset of anti-
FcyR polyspecific mAbs, there were differences in the fine
specificity. TSKI, TSK22, and TSK23, for example, were not
reactive withdsDNA (results not shown) . Wewere concerned,
in particular, with the possible rheumatoid factor activity of
the mAbs, whichwould complicate analysis of the effect the
mAbs had on neutrophil function . The anti-FcyR mAbs did
not exhibit binding to murine IgG1 .
All the mAbs specific for mouse FcyR bind strongly to
human neutrophils (Fig. 1) . Cells stained with FITC-3G8
are -12.5-fold brighter than the isotype control . There are
differences among the staining properties of the five anti-
FcyR mAbs . TSK1 and TSK40 stain somewhat more in-
tensely than TSK22, TSK23, and TSK26 . Since the mAbs
were coupled directly with FITC, we could quantify the
amount of antibody bound by fluorescence spectroscopy. We
found that 72,000 TSK1 IgM molecules bound per neutro-
phil, compared with 480,000 3G8 IgG molecules per cell (Table
1) . Since the IgM is decavalent, the number of IgM TSK1
molecules that bind is probably a 5-10-fold underestimate
of the number of FcyR sites reactive with the antibody.
Human neutrophils express both FcyRII (CD32) and
Fc yRIII-1, (CD16), which is a glycan phosphatidyl inositol
(GPI)-anchored protein . Human neutrophils are reported to
express from 150,000 (23, 33, 34) to 400,000 (35) FcyRIII-1
molecules per cell . The number of FcyRII sites on neutro-
phils is much lower, 15,000-35,000 sites/cell (33, 34) . We
conclude from the number ofIgM TSKI molecules bound
that the mAb must react with FcyRIII. This result is con-
Isotype control
Table 1 . Binding of FITC-TSKI
by mAb 3G8 Fab
mAb
to Neutrophils and Inhibition
Fluorescence intensity
Unstained cells 6.7
Mouse IgM-FITC 14.6
3G8-FITC
5 tug/ml 143.2
0.5 lug/ml 90.2
TSK1-FITC
5 ug/ml 144.7
0.5 jig/ml 73.8
+ 3G8 Fab 0.2 ug/ml 61.4
1 hg/ml 46.1
3 wg/ml 31.4E
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￿
Binding of IgM anti-FcyR mAbs to CHO cells and CHO
cells transfected with human FcyRII . Cells were removed from dishes by
brief treatment with trypsin, and were incubated with mouse IgM (iso-
tope control), mAb IV3, and different anti-FcjR IgM mAbs (1 tug/ml) .
Cells were then incubated with a secondary FITC anti-mouse IgM or
IgG reagent . Meanfluorescence intensities oftheCHO cellswere : isotype
control, 2.301 ; IV.3 Fab, 3.640; TSK1, 39.11; TSK22, 14.41 ; TSK40, 26.09 .
For the CHO cells expressing human Fc yRII, these values were : isotype
control, 2.563; IV3 Fab, 55.55 ; TSK1, 51.23 ; TSK22, 14.81; TSK40, 29.86 .
firmed by the inhibition ofTSK1 binding to neutrophils prein-
cubated with increasing concentrations of3G8 Fab (Table 1) .
To determine if the various TSK antibodies alsobound to
human Fc,RII, we used transfectants expressing Fc yRII . We
first tested a CHO line transfected with FcyRIIa (CW14)
and untransfectedCHO cells. TheCW14 line expressed high
levels of FcyRII, determined by binding o£ mAb IV.3 (Fig.
2) compared with the untransfected control, which was the
same as the isotype control . We determined by Scatchard anal-
ysis that the CW14 line expresses 2.5 x 105 FcyRII mole-
cules/cell (data not shown) . There was no difference in staining
by the TSK mAbs between the control and FcyRII-expres-
singCHO cells. The distribution of CW14 cells that stain
with mAb IV3 (specific for FcyRII) is very broad, indi-
cating considerable heterogeneity in levels ofexpression . How-
ever, the distributions offluorescence intensity ofCHO cells
stained with the TSK mAbs are all relatively narrow. Thus,
Control Cells
Transfected P388D1
human Fc,,Rll-expressing
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Figure 3. Binding of anti-Fc yR IgM mAbs to P388D1 cells and
P388D1 cells transfected with human FcyRII . The PW16 clone made by
transfection with human Fc,RII and the original P388D1 cell line trans-
fected with the opposite orientation ofthe same insert were stained with
TSK22 antibody (1 Ecg/ml). For inhibition studies, samples fromboth types
of cells were preincubated with either 2AG2 or IV.3 mAbs (1 ug/ml, 45
min on ice). This step was followed by incubation with the FITCTSK22
antibody. The values of mean fluorescence intensity for the control cells
were : isotype control, 4.166 ; TSK22, 8.867; 2AG2 + TSK22, 5.605; IV3
+ TSK22, 8.631. For the transformed clone : isotypecontrol, 5.032 ; TSK22,
9.878; 2AG2 + TSK22, 5.605; IV3 + TSK22, 11.30 .
although we do not know what molecule on theCHO cells
reacts with the TSK antibodies, they do not react with the
transfected FcyRII molecule.
To support this conclusion, we examined a mouse macro-
phage cell line, P388D1, transfected with Fc,RII . This cell
line, PW16, expresses 1.2 x 106 FcyRII molecules/cell as de-
termined by Scatchard analysis (data not shown), and also
expresses murine Fc yRII at -2.5 x 105 sites/cell . PW16 and
the control P388D1 cells transfected with the insert in the
opposite orientation, CPW00, show comparable fluorescence
staining by TSK22 (Fig. 3) . The staining of both the trans-
fected and control P388D1 lines is inhibited substantially and
to the same extent by mAb 2.4G2, which reacts specifically
with mouse Fc yRII . There is, however, no inhibition of
TSK22 binding after addition of mAb IV3 . These results
are consistent with the results found for the Fc yRII-
transfected CHO cells (Fig. 2), andshow that theTSK mAbs
do not react with human Fc,RII .
Enzyme Release . All the IgM antibodies specific for
Fc yR triggered neutrophil degranulation . We used /3-gluc-
- Isotype control
r
v FL
TSK22
I ' TSK22 + 2.4G2 IgG
r
TSK22 + IV .3 I9Guronidase and neutrophil elastase as markers for azurophil
granule release and alkaline phosphatase as a marker for specific
granule release. The IgM anti-FcyR mAbs trigger degranu-
lation very efficiently. Enzyme release over background levels
was found at mAb concentrations as low as 0.01 Ag/ml,
(10-ü M) for alkaline phosphatase (Fig. 4 C) . Normal
mouse IgM, even at 10 Wg/ml, did not trigger enzyme re-
lease over background at any time interval. The extent of
degranulation was estimated by measuring the extent of en-
zyme release and normalizing by the total cellular enzyme
present in NP-40 1ysates of neutrophils . The release of neu-
trophil elastase was 25-45% of total (Fig. 4 A), /3-gluc-
uronidase was 10-25% oftotal (Fig. 4 B), and alkaline phos-
phatase was 30-50% of total (Fig . 4 C) . The values are
comparable with the release found after stimulation with
FMLP, which at high concentrations is a potent stimulus of
degranulation (36) .
We found that mAbs 3G8 and IV3 did not trigger de-
granulation (data not shown) . These results are in agreement
with others (37, 38), who found that there was no activa-
tion triggered by anti-Fc yRII or FcyRIII mAbs unless the
mAbs were crosslinked with anti-mouse IgG F(ab')2 . To de-
termine the Fc yR class on the neutrophil plasma membrane
involved in triggering by the TSK anti-Fc yR mAbs, we ex-
amined the effect of preincubating the cells with Fab frag-
ments of mAbs 3G8 and IV3 . The cells were preincubated
with both Fab fragments separately and in combination, and
then the IgM anti-FcyR antibodies were added . There is dra-
matic inhibition in each enzyme assay with all three combi-
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Figure 4 .
￿
Release from neutrophils of hydrolytic en-
zymes after stimulation with IgM anti-FcyR mAbs. We
measured the release of neutrophil elastase (A), 0-gluc-
uronidase (B), and alkaline phosphatase (C) from human
neutrophils (106) incubated with TSK1 (i]) , TSK23 (®),
TSK26 (0), mouse IgM (®), or medium (/) . Neutro-
phils lysed in 1% NP-40 were used to determine the total
cellular enzyme content . Total enzyme activity of the su-
pernatant is normalized as the percentage oftotal cellular
enzyme content.
nations of Fab fragments, even with IV.3 Fab alone (Fig. 5),
thus demonstrating that in a functional assay, both Fc yRII
and FcyRIII are required .
Morphology .
￿
Given the extensive enzyme release triggered
by the autoantibodies, we would expect to observe accom-
panying morphological changes . We examined neutrophils
incubated with mAb TSK23 for 3 min and control cells in-
cubated with normal mouse IgM by scanning electron mi-
croscopy. Averaged over 20 cells, the diameter ofcontrol neu-
trophils was greater (8.2 ± 1.3Am) than that of neutrophils
incubated with TSK23 (6.2 ± 0.6 Am) (p < 0.01) . These
results were confirmed by differential interference contrast
microscopy (results not shown) . The surface morphology of
the cells is dramatically different in the presence of anti-Fc YR
antibody (Fig . 6) . The cells treated with anti-FcyR antibody
(Fig. 6, C and D) lack the large pseudopods and lamellae
seen in control neutrophils (Fig . 6, A and B) .
Transmission electron microscopy was carried to under-
stand better the morphological changes occurring after stim-
ulation with anti-Fc yR antibodies from TSK mice. Relative
to the control neutrophils (Fig. 7 A), the surface of the neu-
trophils incubated withTSK23 (Fig . 7 B) shows fewermem-
brane ruffles and infoldings, in agreement with the scanning
results . The stimulated neutrophils have fewer large storage
vesicles, and a much higher number of small vesicles than
the control neutrophils . These results are consistent with ex-
tensive degranulation, and subsequent internalization of ex-
cessive membrane into smaller vesicles, resulting in a smaller
cell volume .
Figure 5 .
￿
Effect of3G8 Fab and IV.3
Fab on enzyme release of human neu-
tropbils stimulated with IgM anti-
Fc,R mAbs. Neutrophils (106 ) were
preincubated (4°C, 1 h) with Fab frag-
ments (1 Ag/ml), and then IgM anti-
Fc,.R mAbs (1 wg/ml diluted in 10%
(FCS/RPMI) were added for 30 min at
37°C. The neutrophil elastase (A),
ß-glucuronidase (B), and alkaline phos-
phatase (C) enzymatic activity in the
supernatants is expressed as percent of
total cellular enzyme content as in Fig .
4 . Control (/), preincubation with
3G8 Fab (®), preincubation with IV3
Fab (®), preincubation with 3G8 Fab
+ IV3 Fab (®) .Figure 6 .
￿
Scanning electron microscopy of human neutrophils (A andB) and neutrophils treated with TSK23 anti-FcyRmAb (C and D) . Cells
were incubated with the antibody (1 pg/ml) for 3 min . The bar is 5 F.m (x5,000) .
Discussion
Several inbred mouse strains used as models for autoim-
mune diseases, includingNZB, NZB/NZW, TSK, and viable
motheaten mice, have high circulating levels of IgM
anti-mouse F_,RII autoantibody. In old NZB females, -16
Ag/ml, or 2%, of the total IgM bound to an Fc yR affinity
column (4) . We have shown previously that sera from such
mice, as well as IgM anti-Fc yRII mAbs, inhibit macrophage
FcyR-mediated binding of immune complexes. These au-
toantibodies are probably responsible for the FcyR paralysis
seen in peritoneal macrophages from autoimmune mice (5) .
It was thought that high levels of circulating immune com-
plexes in autoimmune mice caused Fc yR paralysis. In sup-
port of our hypothesis, peritoneal macrophages from BXSB
male mice, which have no detectable anti-FcyR Ig but do
have a severe lupus-like syndrome, are normal for macrophage
FcyR function . Anti-RyR autoantibodies have been detected
in human disease as well, indicatingjuvenile neutropenia and
SLE (6-8) . We have preliminary evidence that such anti-
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FcyR antibodies are also present in human scleroderma pa-
tients (unpublished data) .
We have found that the polyspecific anti-FcyR mAbs iso-
lated from TSK mice bind with high avidity tohuman neu-
trophils, and that these autoantibodies efficiently trigger the
release of azurophil and specific granule hydrolases . In con-
trast, mAbs directed against human FcyRIII or FcyRII do
not induce hydrolase release without additional crosslinking
(38, 39) . The difference in efficacy of the anti-FcyR IgM
compared with IgG mAbs may reflect the decavalent nature
of IgM, which more efficiently clusters or crosslinks the
receptors.
The anti-Fc yR mAbs we isolated from the TSK mice, and
the anti-Fr.,R mAbs previously characterized from NZB and
me mice, were all polyspecific (4), binding to a wide range
of cellular antigens including collagen type I and III, and
dsDNA . The polyspecificity of the anti-FcyR mAbs may en-
hance the potential for possible pathogenicity . If the decava-
lent IgM autoantibody binds to collagen, for example, it could
IgM Anti-FcyR Autoantibodies Trigger Neutrophil Degranulationalso bridge to the FcyR of neutrophils or macrophages, ac-
tivating the release of chemotactic factors as well as hydro-
lytic enzymes in the immediate vicinity. Such an antibody
might also play a role in activation of the mesangial cells of
the kidney, which bear FcyRs and can be triggered to re-
lease superoxide (40, 41) . The role of polyspecific antibodies
in autoimmune diseases is not well understood . Some sug-
gest they are only marginally related to autoimmunity, con-
stituting a natural network (42, 43) . However it should be
noted that anti-FcyR autoantibody is not found at detect-
able levels in normal mice (4) .
In determining which FcyR subclass is responsible for de-
granulation by the IgM anti-FcyR mAbs, we found evidence
that the signaling by the GPI-anchored FcyRIII-1 requires
human FcyRII . The anti-FcyR IgM antibodies offer an ad-
vantage in analysis of the signalling requirements since they
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Figure 7.
￿
Transmission electron microscopy ofhuman
neutrophils (A) or neutrophils incubated with the anti-
FcyR mAb TSK23 (B) . Cells were incubated with
TSK23 anti-Fc,.R (1 ug/ml) for 5 min. The bar is 1 urn
(x 11,200).
do not interact with FcyRs via their Fc domains and they
mediate triggering without the need for additional cross-
linking . The dramatic enzyme release triggeredby IgM anti-
Fc yR mAbs is inhibited by mAb 3G8 Fab (directed against
FcyRIII), and by mAb IV.3 Fab (directed against FcyRII) .
The inhibition by mAb3G8 is probably due to displacement
of the IgM anti-FcyR autoantibody, and/or reduction of the
extent ofcrosslinking below the threshold needed to trigger
the neutrophil . The inhibition of neutrophil degranulation
by themAb IV3 Fab is a particularly surprising result, given
the lack of binding of the anti-Fc yR mAbs from TSK mice
to human Fc yRII . The results suggest that signal transduc-
tion may require FcyRII activation subsequent to cross-
linking of the GPI-anchored FcyRIII-1 molecule. This differs
from Kimberly et al . (38), who suggest that FcyRIII alone,
crosslinked with anti-FcyRIII Fab and anti-mouse IgGF(ab')2, can trigger (Caz+]i flux . The same group finds that
Con A-opsonized E also are phagocytosed via Fc yRIII,
which bears high mannose oligosaccharides (44) .
Signal transduction via neutrophil FcyRIII-1 may re-
semble that of other GPI-anchored molecules, such as Thy-1
(45, 46), the Ly-6-encoded molecule T cell activating protein
(TAP) (47, 48), and 5'-nucleotidase (CD73) (49, 50) . Cross-
linking of Thy-1 and TAP results in T cell mitogenesis only
in the presence of a functional CD3/Ti complex . Further-
more, theGPI anchor is required for signalling throughTAP .
Signalling via GPI-anchored proteins also differs fundamen-
tally from the Ti/CD3 complex in that antiTAP mAbs do
not trigger T cell mitogenesis when adsorbed to surfaces,
but only in solution (51) .
Therefore, there is precedent for the hypothesis that anti-
FcyR IgMmAb clustering of neutropbil FcyRIII-1 triggers
signalling by activating FcyRIL For crosslinking of FcyRIII-1
to trigger Fc,RII, one must postulate interaction of ectodo-
mains of the receptors, and/or interaction involving the GPI
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